Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Poor adherence to DOAC therapy requires attention

Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.

Key clinical point: Good adherence is needed for direct-acting oral anticoagulants to outperform warfarin.

Major finding: Thromboembolic events in low-adherence patients were 4.05/100 patient years with a DOAC and 3.37/100 patient years with warfarin.

Study details: Analysis of 83,168 insured U.S. atrial fibrillation patients treated with an oral anticoagulant in 2014-2015.

Disclosures: Dr. Lakkireddy has been a consultant to or has received research support from Biosense Webster, Boehringer Ingelheim, Bristol Myers Squibb, EstechPharma, Janssen, Pfizer, SentreHeart, and St. Jude. Dr. Krahn has been a consultant to Medtronic and has received research support from Medtronic and Boston Scientific.

Source: Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.

Read the article.

Citation:

Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03